Gelteq Commences Veterinary Medicine Clinical Trial to Support an FDA Regulatory Pathway
Rhea-AI Summary
Gelteq (ASX:GELS) has begun its first clinical trial for an antiparasitic drug candidate using Gelteq® technology in the veterinary sector. The study is intended to support an FDA regulatory pathway for animal use, with a potential application targeted later in 2026.
The trial aims to generate data on safety, efficacy and formulation performance in animal health. According to Gelteq, this builds on prior FDA suitability petition acceptance and aligns with its dual-track strategy alongside its commercial nutraceutical portfolio.
Positive
- First veterinary antiparasitic clinical trial using Gelteq® technology initiated
- Trial designed to support an FDA regulatory pathway for animal use in 2026
- Builds on FDA acceptance of Gelteq’s suitability petition for this program
- Positions Gelteq to access an animal health market estimated at USD $78 billion in 2026
- Recent financing cited as providing capital to pursue dual-track pharma and nutraceutical strategy
Negative
- None.
News Market Reaction – GELS
In the May 20 session, GELS gained 16.66%, reflecting a significant positive market reaction. Argus tracked a peak move of +16.3% during that session. Argus tracked a trough of -7.0% from its starting point during tracking. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Clinical trial Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Oct 23 | Preclinical animal trial | Positive | +23.0% | Started preclinical animal trial for gel-based delivery of oily drugs. |
| Sep 05 | Preclinical trial start | Positive | +62.5% | Initiated preclinical bioequivalence study for gel-based antihistamine. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Prior clinical/preclinical trial commencement news for Gelteq saw strong, positive price reactions that aligned with the upbeat tone of those announcements.
Recent Gelteq news around trials has focused on advancing its gel-based delivery platform. In September 2025, it began a preclinical antihistamine bioequivalence study targeting FDA approval, and in October 2025 it launched a preclinical animal trial with Monash University. Both updates delivered sizable positive moves (23.01% and 62.5%). Today’s veterinary antiparasitic clinical trial continues this strategy of using Gelteq® technology across human and animal health markets.
Key Terms
fda regulatory
antiparasitic medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
MELBOURNE, Australia, May 20, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq”) today announced the commencement of its first clinical trial for an antiparasitic drug candidate powered by Gelteq® technology, marking a significant milestone as the Company expands into the veterinary pharmaceutical sector.
The clinical trial seeks to support Gelteq’s planned FDA regulatory pathway for animal use, with the Company targeting a potential application later in 2026.
“This clinical trial represents a significant milestone for Gelteq as we expand into the veterinary pharmaceutical market,” said Nathan Givoni, CEO of Gelteq. “Building on our prior regulatory progress with the FDA, we are now advancing a key drug candidate powered by Gelteq® technology into the clinical stage as we work toward a potential regulatory submission in 2026. This step seeks to reinforce the versatility of Gelteq® technology and its potential across both human and animal health applications.”
Advancing Toward FDA Applications
Commencement of the clinical trial builds on Gelteq’s prior announcement regarding the FDA’s acceptance of its suitability petition, representing a key step in progressing the antiparasitic drug candidate powered by Gelteq® technology toward regulatory approval.
The trial is expected to generate critical data to support the safety, efficacy, and formulation performance of Gelteq® technology in an animal health setting.
Positioned for Continued Clinical and Commercial Progress
With the clinical trial now underway, Gelteq intends to generate data that will support both regulatory progression and future commercial opportunities within the veterinary sector. The global animal health market is estimated to exceed USD
As Gelteq advances this program toward potential regulatory approval, the Company believes it is strategically positioned to participate in a large and growing market segment, where improved delivery formats may offer meaningful advantages in compliance and dosing.
With Gelteq’s recent financing, the Company believes it is well positioned with sufficient capital to execute on its dual-track strategy of advancing pharmaceutical programs for long-term value while continuing to drive near-term revenue through its commercial nutraceutical portfolio.
About Gelteq Ltd.
Headquartered in Melbourne, Australia, Gelteq (NASDAQ: GELS) is a biotechnology company that has developed a novel drug delivery platform in an ingestible gel form. Gelteq® technology, a proprietary delivery technology, is designed to improve how active ingredients are formulated, stabilised and absorbed by the body. Gelteq specializes in research and development, product creation and manufacturing for partners across pharmaceutical, consumer health and animal health markets. Gelteq® technology aims to address challenges associated with conventional drug and nutrient delivery by enhancing bioavailability, improving patient compliance, and enabling precise dosing. For more information, visit www.gelteq.com
Gelteq Contact:
Investor Relations
Matt Kreps, Darrow Associates IR
+1-214-597-8200
mkreps@darrowir.com
Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained herein are forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied in such statements. For a discussion of these risks and uncertainties, refer to Gelteq’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F filed on November 17, 2025. Gelteq undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.
1 Fortune Business Insights. (2025). Animal health market size, share & industry analysis. Report ID: FBI102371
